Is it necessary to receive the 13-valent vaccine?

The 13-valent pneumococcal vaccine is a self-funded (non-government-subsidized) vaccine. If financially feasible, vaccination is strongly recommended. This vaccine—formally known as the 13-valent pneumococcal conjugate vaccine (PCV13)—protects against infections caused by 13 different serotypes of *Streptococcus pneumoniae*.

However, PCV13 only prevents pneumonia caused by the specific pneumococcal serotypes included in the vaccine; it offers no protection against pneumonia or otitis media caused by other pneumococcal serotypes or by other microorganisms.

Nonetheless, vaccination is especially critical for infants and young children, as well as for older adults. Children under five years of age and adults aged 60 years and older typically have significantly weakened immune defenses, rendering them highly susceptible to pathogenic bacteria—including *Streptococcus pneumoniae*. Consequently, their risk of developing pneumococcal pneumonia is substantially elevated. Therefore, administering PCV13 is highly advisable for these populations.

Parents are advised to choose PCV13 over the 7-valent or 23-valent pneumococcal vaccines for their infants because: (1) the 7-valent vaccine covers fewer serotypes and thus provides narrower protection than PCV13; and (2) although the 23-valent pneumococcal polysaccharide vaccine (PPSV23) targets more serotypes, it induces weaker and shorter-lived immunity in infants and young children. Overall, considering immunogenicity, duration of protection, and safety profile, PCV13 is the most appropriate choice for infant vaccination.